{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.37","value":"5.77"},{"groupId":"OG001","spread":"1.08","value":"5.54"},{"groupId":"OG002","spread":"1.17","value":"5.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"DS-8201a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.82","value":"7.46"},{"groupId":"OG001","spread":"1.00","value":"6.40"},{"groupId":"OG002","spread":"1.73","value":"6.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"DS-8201a, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.22","value":"6.20"},{"groupId":"OG001","spread":"1.01","value":"5.54"},{"groupId":"OG002","spread":"1.51","value":"5.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Total Anti-HER2 antibody, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.04","value":"8.00"},{"groupId":"OG001","spread":"2.10","value":"7.90"},{"groupId":"OG002","spread":"1.15","value":"6.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Total Anti-HER2 antibody, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.11","value":"5.50"},{"groupId":"OG001","spread":"0.939","value":"5.21"},{"groupId":"OG002","spread":"1.19","value":"5.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"MAAA-1181a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.65","value":"7.01"},{"groupId":"OG001","spread":"1.02","value":"6.18"},{"groupId":"OG002","spread":"1.10","value":"5.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"MAAA-1181a, Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"description":"Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Terminal elimination half-life (t1/2) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG001","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG002","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic parameters were assessed in patients with available data in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)","title":"Pharmacokinetic Parameter Terminal Elimination Half-life (t1/2) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a","type":"SECONDARY","unitOfMeasure":"days"}